Sign In
Buy CSU
$33.30
+0 (+0%)
At Close: Jul 20, 2022
Constellation Software Inc. Announces Release Date for Third Quarter Results
08:51pm, Tuesday, 15'th Oct 2024
TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its third quarter results on November 8, 2024.
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
01:05am, Wednesday, 11'th Sep 2024
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary an
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in
Constellation Software Inc. Announces Results for the Second Quarter Ended June 30, 2024 and Declares Quarterly Dividend
05:01pm, Friday, 09'th Aug 2024
TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30,
Constellation Software Inc. Announces Release Date for Second Quarter Results
07:31pm, Monday, 15'th Jul 2024
TORONTO, July 15, 2024 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its second quarter results on August 9, 2024.
Vervotech Honored as "Most Collaborative Partner 2023" by HBX Group
11:59am, Friday, 31'st May 2024
DUBAI, United Arab Emirates--(BUSINESS WIRE)---- $CSU #AI--Vervotech is proud to announce that it has been awarded the title of "Most Collaborative Partner 2023 – Saudi Arabia" by HBX Group.
Stealth Mode Standouts: 3 Under-the-Radar Tech Stocks Set to Soar
08:16am, Tuesday, 12'th Mar 2024
Tech stocks continue to outperform. The Nasdaq index is up nearly 10% this year compared to an 8% increase in the benchmark S&P 500 index and a 3% gain in the blue-chip Dow Jones Industrial Average.
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
01:00am, Friday, 16'th Feb 2024
Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to p
Secret Stock Alert: 3 Overlooked Picks Set for Massive Growth
09:00am, Saturday, 13'th Jan 2024
Call them secret stocks or hidden gems. While the media tends to trumpet the same stocks repeatedly, plenty of stocks get almost zero notice.
Juniper Group Acquires Vervotech, a Leading Hotel and Room Mapping Solutions Provider
03:00am, Friday, 18'th Aug 2023
PALMA, Spain--(BUSINESS WIRE)---- $CSU #ConstellationSoftware--Juniper Group is excited to announce the successful acquisition of Vervotech, a tech start-up making significant strides in the Travel In
Constellation Software’s Perseus Group Completes
07:30am, Tuesday, 16'th May 2023
TORONTO, May 16, 2023 (GLOBE NEWSWIRE) — Constellation Software Inc. (“Constellation”) (TSX: CSU) announced today that it has, through its Perseus Group (“Perseus”), completed the purchase o
German conservatives' meeting with controversial US governor slammed
08:00am, Saturday, 06'th May 2023
A meeting of German opposition conservative politicians with controversial Florida Governor Ron DeSantis has sparked criticism. The politicians are from the Christian Social Union (CSU), the sister pa
Press Release of Constellation Software Inc.
07:05pm, Thursday, 04'th May 2023
TORONTO, May 04, 2023 (GLOBE NEWSWIRE) — On April 3 2023 Constellation Software Inc. (“Constellation”) (TSX: CSU) was subject to a cyber-security incident (the “Incident”) that impacted a li
Constellation Software’s Perseus Group Enters into
07:43pm, Friday, 24'th Mar 2023
TORONTO, March 24, 2023 (GLOBE NEWSWIRE) — Constellation Software Inc. (“Constellation”) (TSX: CSU) today announced that its Perseus operating group has entered into a binding commitment to acqu
Dupixent ® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
